![](https://library.celltelligence.com/wp-content/uploads/2024/02/Screenshot-2024-02-21-at-18.48.03.png)
$0
Amtagvi Becomes the First Approved T-Cell Therapy in Solid Tumors
On Friday, February 16, Iovance Biotherapeutics announced (press release) that the FDA granted accelerated approval to Amtagvi (lifileucel), a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy to treat adult patients with unresectable or metastatic melanoma after anti-PD1 and targeted therapy. Below, Celltelligence provides insights on the importance of Amtagvi’s approval in the solid tumors field, while discussing Iovance’s plans and pipeline.